Cargando…

CLSI announces availability of new CLSI microbiology documents

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2007
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135317/ https://www.ncbi.nlm.nih.gov/pubmed/32287680 http://dx.doi.org/10.1016/j.clinmicnews.2007.03.002

Ejemplares similares

Susceptibility of Dermatophytes to Thiabendazole Using CLSI Broth Macrodilution
por: Robledo-Leal, Efrén, et al.
Publicado: (2012)

Time to switch from CLSI to EUCAST? A Southeast Asian perspective
por: Cusack, T.P., et al.
Publicado: (2019)

CLSI broth microdilution method for testing susceptibility of Malassezia pachydermatis to thiabendazole
por: Nascente, Patrícia da Silva, et al.
Publicado: (2009)

Comparison of clinical antibiotic susceptibility testing interpretations to CLSI standard interpretations
por: Hitchingham, Erin, et al.
Publicado: (2023)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

Antifungal susceptibility profile of Trichosporon isolates: correlation between CLSI and etest methodologies
por: Lemes, Raquel M.L., et al.
Publicado: (2010)

Molecular Identification and Antifungal Susceptibility Patterns of Clinical Dermatophytes Following CLSI and EUCAST Guidelines
por: Dabas, Yubhisha, et al.
Publicado: (2017)

CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa
por: Karita, Etienne, et al.
Publicado: (2009)

A Pharmacovigilance Analysis of Daptomycin Use Based on CLSI Susceptible Dose-Dependent Category
por: Zhang, Ming M., et al.
Publicado: (2023)

Change of Antibiotic Susceptibility Testing Guidelines from CLSI to EUCAST: Influence on Cumulative Hospital Antibiograms
por: Wolfensberger, Aline, et al.
Publicado: (2013)

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates
por: Buil, Jochem B., et al.
Publicado: (2018)

656. Sulbactam-Durlobactam MIC Determination: Comparative Evaluation of the New ETEST(®) SUD to the CLSI 2021 Broth Microdilution Method
por: Sauvonnet, Veronique, et al.
Publicado: (2021)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Provisional Use of CLSI-Approved Quality Control Strains for Antimicrobial Susceptibility Testing of Mycoplasma (‘Mesomycoplasma’) hyorhinis
por: Käbisch, Lisa, et al.
Publicado: (2021)

Impact of CLSI Break Point Changes Over the Past Decade on Antimicrobial Susceptibility in Gram-Negative Bacteria
por: Johnson, Wesley, et al.
Publicado: (2021)

356. Impact of CLSI Breakpoint Changes on Unit-Specific Combination Antibiograms for Gram-Negative Respiratory Isolates
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

Laboratory evaluation of the Sigma Transwab® transport system for the recovery of Candida species using the Clinical and Laboratory Standards Institute (CLSI) document M40-A2
por: Elcocks, E., et al.
Publicado: (2020)

In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values
por: Jang, Min Joong, et al.
Publicado: (2013)

CLSI based antibiogram profile and the detection of MDR and XDR strains of Acinetobacter baumannii isolated from urine samples
por: Girija AS, Smiline, et al.
Publicado: (2019)

2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Quality Control MIC Ranges Used for Telavancin with Application of a Revised CLSI Reference Broth Microdilution Method
por: Ross, James E., et al.
Publicado: (2014)

644. Comparative Evaluation of ETEST® ERV bioMérieux with the CLSI Broth Microdilution Method for Eravacycline MIC Determination
por: Sauvonnet, Veronique, et al.
Publicado: (2019)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

Prevalence of susceptibility patterns of opportunistic bacteria in line with CLSI or EUCAST among Haemophilus parainfluenzae isolated from respiratory microbiota
por: Kosikowska, Urszula, et al.
Publicado: (2020)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

Impact of the phlebotomy training based on CLSI/NCCLS H03-A6 - procedures for the collection of diagnostic blood specimens by venipuncture.
por: Lima-Oliveira, Gabriel, et al.
Publicado: (2012)

The effective reduction of tourniquet application time after minor modification of the CLSI H03-A6 blood collection procedure
por: Lima-Oliveira, Gabriel, et al.
Publicado: (2013)

Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision
por: Wang, Ying, et al.
Publicado: (2021)

In Vitro Azole and Amphotericin B Susceptibilities of Malassezia furfur from Bloodstream Infections Using E-Test and CLSI Broth Microdilution Methods
por: Rhimi, Wafa, et al.
Publicado: (2020)

Comparison of M.I.C.E. and Etest with CLSI Agar Dilution for Antimicrobial Susceptibility Testing against Oxacillin-Resistant Staphylococcus spp
por: Campana, Eloiza H., et al.
Publicado: (2014)

Research and discussion on the evaluation scheme of reagent lot‐to‐lot differences in 16 chemiluminescence analytes, established by the EP26‐A guidelines of the CLSI
por: Tao, Ran, et al.
Publicado: (2020)

Comparative assessment of CDS, CLSI disc diffusion and Etest techniques for antimicrobial susceptibility testing of Neisseria gonorrhoeae: a 6-year study
por: Singh, Vikram, et al.
Publicado: (2012)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

230. Multicenter Assessment of the Accuracy of MIC Results for Colistin with MicroScan Dried Gram Negative MIC Panels using CLSI Breakpoints
por: Riedel, Stefan, et al.
Publicado: (2022)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

Haemophilus influenzae blood-stream infection and third-generation cephalosporin susceptibility testing: a comparative case study using EUCAST and CLSI guidelines
por: Merlino, John, et al.
Publicado: (2023)

In vitro antifungal susceptibilities of Candida species to liposomal amphotericin B, determined using CLSI broth microdilution, and amphotericin B deoxycholate, measured using the Etest
por: Lovero, Grazia, et al.
Publicado: (2017)

Comparison of Clinical Laboratory Standards Institute (CLSI) Microdilution Method and VITEK 2 Automated Antifungal Susceptibility System for the Determination of Antifungal Susceptibility of Candida Species
por: Dalyan Cilo, Burcu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_61s55u55j0usq9ne8o5loqt058